| Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.Breast Cancer Res | PMID 34425869PMC8381581 | 2021-Aug-23 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Randomized Phase II Study to Comparing Docetaxel/Nedaplatin versus Docetaxel for 5-Fluorouracil/Cisplatin Resistant Esophageal Squamous Cell Carcinoma.Ann Thorac Cardiovasc Surg | PMID 33408308PMC8374090 | 2021-Aug-20 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Low-pressure versus standard pressure laparoscopic colorectal surgery (PAROS trial): a phase III randomized controlled trial.Br J Surg | PMID 33755088无 PMCID | 2021-Aug-19 | 0.93 | 干预为非药物单独策略,未满足药物干预要求。 | 待处理 |
| Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.N Engl J Med | PMID 34407342无 PMCID | 2021-Aug-19 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Atogepant for the Preventive Treatment of Migraine.N Engl J Med | PMID 34407343无 PMCID | 2021-Aug-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Bacterial Mucosal Immunotherapy with MV130 Prevents Recurrent Wheezing in Children: A Randomized, Double-Blind, Placebo-controlled Clinical Trial.Am J Respir Crit Care Med | PMID 33705665PMC8480240 | 2021-Aug-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP).Sci Bull (Beijing) | PMID 36654286无 PMCID | 2021-Aug-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, phase 3 trial (CMAS).Sci Bull (Beijing) | PMID 36654287无 PMCID | 2021-Aug-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.Lancet | PMID 34370970无 PMCID | 2021-Aug-14 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial.Crit Care | PMID 34380538PMC8356211 | 2021-Aug-11 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131.J Clin Oncol | PMID 34092112PMC8577688 | 2021-Aug-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.BMC Cancer | PMID 34364385PMC8349489 | 2021-Aug-07 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.N Engl J Med | PMID 34170647无 PMCID | 2021-Aug-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Comparing Patient-Controlled Analgesia Versus Non-PCA Hydromorphone Titration for Severe Cancer Pain: A Randomized Phase III Trial.J Natl Compr Canc Netw | PMID 34343968无 PMCID | 2021-Aug-03 | 0.95 | While the record meets many criteria (Phase III, randomized, human, oncology context, time-to-event endpoint, original results), the intervention (hydromorphone for pain control) is a supportive care measure for cancer pain, not an anti-neoplastic drug therapy aimed at treating the malignant neoplasm itself. The cohort requires a drug-containing intervention for the oncology indication. | 待处理 |
| Long-term efficacy and safety of sapropterin in patients who initiated sapropterin at < 4 years of age with phenylketonuria: results of the 3-year extension of the SPARK open-label, multicentre, randomised phase IIIb trial.Orphanet J Rare Dis | PMID 34344399PMC8335897 | 2021-Aug-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Neurocognitive functioning and radiologic changes in primary CNS lymphoma patients: results from the HOVON 105/ALLG NHL 24 randomized controlled trial.Neuro Oncol | PMID 33560442PMC8328030 | 2021-Aug-02 | 0.95 | The record is from a phase III randomized oncology trial (HOVON 105/ALLG NHL 24) but reports neurocognitive and radiological outcomes only. It does not contain the required survival, progression, recurrence, death, or time-to-event efficacy outcomes for KM digitization. | 待处理 |
| Comparative Efficacy of a High-Dose vs Standard-Dose Hepatitis B Revaccination Schedule Among Patients With HIV: A Randomized Clinical Trial.JAMA Netw Open | PMID 34424307PMC8383137 | 2021-Aug-02 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A Randomized Controlled Trial of Local Delivery of a Rho Inhibitor (VX-210) in Patients with Acute Traumatic Cervical Spinal Cord Injury.J Neurotrauma | PMID 33559524PMC8309435 | 2021-Aug-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-Term Outcomes of Radical Radiation Therapy with Hypoxia Modification with Biomarker Discovery for Stratification: 10-Year Update of the BCON (Bladder Carbogen Nicotinamide) Phase 3 Randomized Trial (ISRCTN45938399).Int J Radiat Oncol Biol Phys | PMID 33689854无 PMCID | 2021-Aug-01 | 0.80 | The trial meets criteria for oncology, human, randomized, Phase III, time-to-event endpoint, and original long-term results. However, the intervention (carbogen and nicotinamide for hypoxia modification) is not considered a conventional drug intervention as per the inclusion criteria, which requires a drug-containing intervention (e.g., cytotoxic, targeted, immunotherapy). | 待处理 |
| Resolution of organ dysfunction as a predictor of long-term survival in necrotizing soft tissue infections: Analysis of the AB103 Clinical Composite Endpoint Study in Necrotizing Soft Tissue Infections trial and a retrospective claims database-linked chart study.J Trauma Acute Care Surg | PMID 33797490无 PMCID | 2021-Aug-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance).J Clin Oncol | PMID 33989025PMC8462587 | 2021-Aug-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A Randomized Controlled Trial Comparing Two Different Schedules for Cisplatin Treatment in Patients with Locoregionally Advanced Nasopharyngeal Cancer.Clin Cancer Res | PMID 34083231PMC8974421 | 2021-Aug-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.J Clin Oncol | PMID 34111952无 PMCID | 2021-Aug-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma: The NEOCRTEC5010 Randomized Clinical Trial.JAMA Surg | PMID 34160577PMC8223138 | 2021-Aug-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non-Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial.JAMA Oncol | PMID 34165501PMC8227450 | 2021-Aug-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial.JAMA Oncol | PMID 34165508PMC8227465 | 2021-Aug-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Quadrivalent Human Papillomavirus Vaccine in Boys and Girls 9-13 Years of Age in Malaysia: A Phase IIIb, Randomized, Open-label Study.Pediatr Infect Dis J | PMID 34250977PMC8274580 | 2021-Aug-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Serious Gastrointestinal-Related Adverse Events Among Psoriasis Patients Treated With Guselkumab in VOYAGE 1 and VOYAGE 2.J Drugs Dermatol | PMID 34397205无 PMCID | 2021-Aug-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Fixed-Combination Halobetasol Propionate/Tazarotene Lotion for Psoriasis in Patients With 3%-5% Affected Body Surface Area.J Drugs Dermatol | PMID 34397206无 PMCID | 2021-Aug-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Cost-effectiveness of nivolumab in patients with NSCLC in the United States.Am J Manag Care | PMID 34460179无 PMCID | 2021-Aug-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2.J Dermatolog Treat | PMID 31613178无 PMCID | 2021-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of neuronox® for lateral canthal lines: a phase I/III, multicenter, randomized, double-blind, active-controlled study.J Dermatolog Treat | PMID 31665942无 PMCID | 2021-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Randomized Trials of Retosiban Versus Placebo or Atosiban in Spontaneous Preterm Labor.Am J Perinatol | PMID 32380566无 PMCID | 2021-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial.J Am Acad Dermatol | PMID 33253833无 PMCID | 2021-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of the novel dual orexin receptor antagonist daridorexant on night-time respiratory function and sleep in patients with moderate chronic obstructive pulmonary disease.J Sleep Res | PMID 33417730无 PMCID | 2021-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A glycopyrronium bromide 1% cream for topical treatment of primary axillary hyperhidrosis: efficacy and safety results from a phase IIIa randomized controlled trial.Br J Dermatol | PMID 33445205PMC8451866 | 2021-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of once-daily glucagon-like peptide-1 receptor agonist lixisenatide as an add-on treatment to basal insulin in Asian and white adults with type 2 diabetes mellitus: An individual-level pooled analysis of phase III studies.J Diabetes Investig | PMID 33475222PMC8354505 | 2021-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial.Leukemia | PMID 33483613无 PMCID | 2021-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Romosozumab efficacy on fracture outcomes is greater in patients at high baseline fracture risk: a post hoc analysis of the first year of the frame study.Osteoporos Int | PMID 33537844PMC8376732 | 2021-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia.Leukemia | PMID 33542479PMC8324476 | 2021-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2).Br J Dermatol | PMID 33544883无 PMCID | 2021-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effects of glutamine for prevention of radiation-induced esophagitis: a double-blind placebo-controlled trial.Invest New Drugs | PMID 33580845PMC11948488 | 2021-Aug | 0.95 | The trial is randomized, Phase III, in oncology patients, and evaluates a drug intervention (glutamine). However, the primary endpoint is the incidence and severity of radiation-induced esophagitis, which is a toxicity/preventive endpoint, not a time-to-event efficacy endpoint such as overall survival, progression-free survival, or disease-free survival. The abstract does not report Kaplan-Meier curves or hazard ratios for such an endpoint. | 待处理 |
| A Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis.J Rheumatol | PMID 33589554无 PMCID | 2021-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| First-line Treatment with Ribociclib plus Endocrine Therapy for Premenopausal Women with Hormone-receptor-positive Advanced Breast Cancer: A Cost-effectiveness Analysis.Clin Breast Cancer | PMID 33676870无 PMCID | 2021-Aug | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| EVO100 prevents chlamydia and gonorrhea in women at high risk of infection.Am J Obstet Gynecol | PMID 33705748无 PMCID | 2021-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Ribociclib Population Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Analysis of Neutrophils in Cancer Patients.J Clin Pharmacol | PMID 33713359无 PMCID | 2021-Aug | 0.85 | The record is a Phase III randomized trial in oncology with a drug intervention, but it reports only pharmacokinetic and pharmacodynamic modeling for safety (neutropenia), not primary or key secondary time-to-event efficacy outcomes like OS or PFS. Therefore, it does not meet the inclusion criterion for a time-to-event efficacy endpoint. | 待处理 |
| Secukinumab Efficacy on Enthesitis in Patients With Ankylosing Spondylitis: Pooled Analysis of Four Pivotal Phase III Studies.J Rheumatol | PMID 33722947无 PMCID | 2021-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| pUDK-HGF Gene Therapy to Relieve CLI Rest Pain and Ulcer: A Phase II, Double-Blind, Randomized Placebo-Controlled Trial.Hum Gene Ther | PMID 33726499无 PMCID | 2021-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.Diabetes Obes Metab | PMID 33769656无 PMCID | 2021-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of LY2963016 insulin glargine versus insulin glargine (Lantus) in Chinese adults with type 2 diabetes: A phase III, randomized, open-label, controlled trial.Diabetes Obes Metab | PMID 33783964PMC8361736 | 2021-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |